Johnson & Johnson Halts Promising Depression Drug Aticaprant, Casting Shadow on Kappa Opioid Receptor Research March 9, 2025
Johnson & Johnson’s Aticaprant Setback Shakes Depression Treatment Landscape, Impacting Biotech Startups and Industry Optimism March 9, 2025
Johnson & Johnson Halts Aticaprant Development, Shifting Focus Amidsetbacks in Depression Treatment Research March 8, 2025
Johnson & Johnson’s Aticaprant Development Halt: A Blow to Kappa Opioid Therapies and Market Reactions March 8, 2025
Johnson & Johnson’s Aticaprant Setback Sends Shockwaves Through Depression Treatment Landscape March 8, 2025
Johnson & Johnson Halts Aticaprant Development, Casting Doubts on Kappa Opioid Receptor Drugs for Depression March 8, 2025
Johnson & Johnson Halts Promising Depression Drug Aticaprant Amid Efficacy Concerns, Shaking Biotech Sector March 8, 2025
Johnson & Johnson Halts Promising Depression Drug Aticaprant, Shaking Up Pharmaceutical Landscape March 7, 2025
UnitedHealth Paves the Way for Non-Opioid Pain Management with Coverage for Vertex’s Journavx March 7, 2025
